文献速递血液净化与透析

FDA对血液透析血管通路研究的监管视角

FDA Regulatory Perspectives for Studies on Hemodialysis Vascular Access.
PubMed 文献 · Clin J Am Soc Nephrol · 2017-07-24

美国肾脏病学会与FDA于2012年合作成立肾脏健康倡议(KHI),聚焦血液透析血管通路产品,旨在明确合适的试验终点以支持临床、监管和报销决策。KHI召集专家团队针对移植物动静脉瘘、自体动静脉瘘和中心静脉导管分别提出建议。本文概述FDA监管中心及相关法规,并阐述FDA对KHI团队所提问题和终点的看法,认为标准化定义和临床试验终点是促进该领域创新的重要进展。

要点

  • KHI项目旨在明确血液透析血管通路的临床试验终点以支持监管决策。
  • 缺乏统一定义和终点共识被视为该领域创新的障碍。
  • FDA对KHI提出的标准化定义和终点表示认可,认为其促进创新。

核心结论

  • KHI团队提出的标准化定义和临床试验终点是改善血液透析血管通路领域创新的重要一步。

研究设计与样本

  • 美国肾脏病学会与FDA于2012年合作成立KHI,并召集专家团队针对三类血管通路提出建议。

主要发现

  • 缺乏统一定义和试验终点共识被视为血液透析血管通路领域创新的障碍。

临床怎么用

  • 临床可参考KHI提出的标准化定义和临床试验终点设计血液透析血管通路研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In an effort to foster innovation and new product development, the American Society of Nephrology and the US Food and Drug Administration partnered to form the Kidney Health Initiative in 2012. Part of the Kidney Health Initiative's mission is to foster development of therapies by creating a collaborative environment where the US Food and Drug Administration and the greater nephrology community can interact to optimize product evaluation. This particular Kidney Health Initiative project focused on products related to hemodialysis vascular access, with the goal of clarifying appropriate trial end points that could subsequently inform clinical, regulatory, and coverage decisions. Both the lack of common definitions and the lack of consensus on trial end points have been viewed as barriers to innovation in this area. Toward this end, the Kidney Health Initiative convened teams of expert stakeholders to address these issues for each major vascular access category (arteriovenous grafts, arteriovenous fistulas, and central venous catheters), and each team provided recommendations. This commentary provides an overview of the US Food and Drug Administration centers that regulate hemodialysis vascular access and certain laws and regulations that affect these products as well as our perspectives on some of the issues raised and end points proposed by the Kidney Health Initiative teams. The standardized definitions and clinical trial end points proposed by the teams represent an important step forward to improve innovation in this area.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Hurst FP, Lee RE, Thompson AM, et al. FDA Regulatory Perspectives for Studies on Hemodialysis Vascular Access. Clin J Am Soc Nephrol. 2017. PMID: 28739575. doi:10.2215/CJN.02900317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。